STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials

BACKGROUND: Severe, early-onset fetal growth restriction due to placental insufficiency is associated with a high risk of perinatal mortality and morbidity with long-lasting sequelae. Placental insufficiency is the result of abnormal formation and function of the placenta with inadequate remodelling of the maternal spiral arteries. There is currently no effective therapy available. Some evidence suggests sildenafil citrate may improve uteroplacental blood flow, fetal growth, and meaningful infant outcomes. The objective of the Sildenafil TheRapy In Dismal prognosis Early onset fetal growth Res... Mehr ...

Verfasser: Pels, A
Kenny, LC
Alfirevic, Z
Baker, PN
von Dadelszen, P
Gluud, C
Kariya, CT
Mol, BW
Papageorghiou, AT
van Wassenaer-Leemhuis, AG
Ganzevoort, W
Groom, KM
international STRIDER Consortium
Dokumenttyp: Artikel
Erscheinungsdatum: 2017
Schlagwörter: Fetal growth restriction / Neonatal morbidity / Neonatal mortality / Placental insufficiency / Randomised placebo controlled trial / Sildenafil / Adult / Australia / Canada / Clinical Protocols / Female / Fetal Growth Retardation / Gestational Age / Humans / International Cooperation / Ireland / Netherlands / New Zealand / Pregnancy / Pregnancy Outcome / Prognosis / Sildenafil Citrate / Treatment Outcome / United Kingdom / Vasodilator Agents / Young Adult
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26820698
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://discovery.ucl.ac.uk/id/eprint/10082291/1/s12884-017-1594-z.pdf